Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRNVAC1 in AML
NCT00510133Phase 2Completed
- Sponsor
- Asterias Biotherapeutics
- Start
- Jul 2007
- Primary completion
- Dec 2011
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hTERT-DC vaccine in acute myeloid leukemia (AML), sponsored by Asterias Biotherapeutics. Primary endpoint: Feasibility of Vaccine Manufacturing and Administration at 1 year. Started Jul 2007; status: completed.
02
Drugs
hTERT-DC vaccine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00510133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00510133.